Edward Tobinick

Edward Tobinick

Edward Lewis Tobinick is an American physician currently in full-time private practice in Los Angeles, California and he is an Assistant Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA. [ [http://www.newsroom.ucla.edu/portal/ucla/ucla-headlines-jan-11-2008-43001.aspx UCLA Headlines Jan. 11, 2008 / UCLA Newsroom ] ] Dr. Tobinick is co-author of the recent case report documenting rapid clinical improvement in a patient with Alzheimer's disease following perispinal administration of etanercept [ [http://www.jneuroinflammation.com/content/5/1/2 Journal of Neuroinflammation | Full text | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration ] ] which has been received with considerable interest [ [http://www.jneuroinflammation.com/content/5/1/3 Journal of Neuroinflammation | Full text | Perispinal etanercept: Potential as an Alzheimer therapeutic ] ] [ [http://www.newsroom.ucla.edu/portal/ucla/ucla-headlines-jan-11-2008-43001.aspx UCLA Headlines Jan. 11, 2008 / UCLA Newsroom ] ] .

Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis. [ [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=8&f=G&l=50&co1=AND&d=PTXT&s1=tobinick&OS=tobinick&RS=tobinick United States Patent 6,423,321] ] In addition, he originated the concept of the potential utility of etanercept, alone or in combination with oseltamivir for treatment of influenza (U.S. patent 6,419,934, filed September 5, 2000 [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=29&f=G&l=50&co1=AND&d=PTXT&s1=tobinick&OS=tobinick&RS=tobinick] ). For these novel treatment methods he has been issued multiple U.S. patents, including 6,015,557 (Tumor necrosis factor antagonists for the treatment of neurological disorders) [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=41&f=G&l=50&co1=AND&d=PTXT&s1=tobinick&OS=tobinick&RS=tobinick] ; 6,177,077 [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=35&f=G&l=50&co1=AND&d=PTXT&s1=tobinick&OS=tobinick&RS=tobinick] ; 6,419,934 [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=29&f=G&l=50&co1=AND&d=PTXT&s1=tobinick&OS=tobinick&RS=tobinick] ; and 6,982,089 [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=8&f=G&l=50&co1=AND&d=PTXT&s1=tobinick&OS=tobinick&RS=tobinick] . In general, his concepts represent emerging therapeutic strategies supported by small pilot studies and expert reviews. (see 2007 Citations, below). [ [http://www.nrimed.com/bio.htm Tobinick's private practice] ]

Tobinick earned his M.D. from the UC San Diego School of Medicine in 1977.


* cite book
last = Tobinick | first = Edward
coauthors = Richard Usatine, Ronald Moy, Daniel Siegel
title = Skin Surgery: A Practical Guide
location = St. Louis
publisher = Mosby
year = 1998
id = ISBN 0-8151-7362-8


In 2007 the following scientific publications have cited Tobinick publications:Scientific Articles:
*1. Uceyler N, Sommer C. Cytokine-induced Pain: Basic Science and Clinical Implications. Reviews in Analgesia 2007;9(2):87-103.
*2. Tweedie D, Sambamurti K, Greig NH. Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, US. TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Curr Alzheimer Res. 2007 Sep;4(4):375-8.
*2. Tubbs RS, Hansasuta A, Loukas M, Louis RG, Jr., Shoja MM, Salter EG, et al. The basilar venous plexus. Clin Anat 2007.
*3. Saxena AK, Kumar S. Management strategies for pain in breast carcinoma patients: current opinions and future perspectives. Pain Pract 2007;7(2):163-77.
*4. Owlia MB, Salimzadeh A, Alishiri G, Haghighi A. Comparison of two doses of corticosteroid in epidural steroid injection for lumbar radicular pain. Singapore Med J 2007;48(3):241-5.
*5. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, et al. A novel p38alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 2007;4(1):21.
*6. Hu W, Ranaivo HR, Roy SM, Behanna HA, Wing LK, Munoz L, et al. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 2007;17(2):414-8.
*7. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. Arthritis Res Ther. 2007 Aug 9;9(4):R77.

Hardcover/ Bound Texts:
*1. Neuroinflammation in Neuronal Death and Repair, Volume 82 (International Review of Neurobiology.) G. Bagetta, editor (Hardcover - Jul 16, 2007) Amsterdam ; Boston : Elsevier Academic Press ©2007. ISBN 9780123739896 0123739896.
*2. Interactions Between Neurons and Glia in Aging and Disease by Joao Malva, Ana Cristina Rego, Rodrigo Cunha, and Catarina Oliveira (Eds.) (Hardcover - Aug 22, 2007). 2007, Approx. 535 p., Hardcover ISBN 978-0-387-70829-4 New York ; London : Springer, 2007.
*3. Cytokines in the Genesis and Treatment of Cancer (Cancer Drug Discovery and Development) by Michael A. Caligiuri and Michael T. Lotze (Hardcover - April 20, 2007) Totowa, N.J. : Humana Press ©2007. ISBN 9780896038202 0896038203 9781597454551 1597454559.
*4. Chapter 10: Anti-TNF-alpha antibody and cancer cachexia, The ASCRS Textbook of Colon and Rectal Surgery by J.M. Church, J. Garcia-Aguilar, P.L. Roberts, and T.J. Saclarides; New York : Springer ©2007. ISBN 9780387248462 0387248463.
*5. Spinal Reconstruction: Clinical Examples of Applied Basic Science, Biomechanics and Engineering by Kai-Uwe Lewandrowski, Michael J. Yaszemski, Iain Kalfas, and Paul Park (Hardcover - Feb 12, 2007) New York : Informa Healthcare ©2007. ISBN 9780849398155 0849398150.
*6. Olesen J, Jensen T. From Basic Pain Mechanisms to Headache. Oxford University Press 2007.
*7. Neuroimmunology: The Immune System and Alzheimers, in the 2007 Progress Report on Brain Research, Dana Alliance for Brain Initiatives, Dana Press, New York ©2007.


* [http://www.medscape.com/viewarticle/530141 link]

External links

* [http://www.tobinick.com/ Edward Tobinick]
* [http://www.nrimed.com/ Institute for Neurological Research, a private medical group, inc.]

Wikimedia Foundation. 2010.

Игры ⚽ Нужно решить контрольную?

Look at other dictionaries:

  • Primary progressive aphasia — (PPA) is a type of dementia characterized most prominently by an insidious and progressive disorder of language and speech abilities. It was first described by Marsel Mesulam in 1982. There is no approved treatment. Rapid and sustained… …   Wikipedia

  • University of California at San Diego School of Medicine — Infobox University image size = 150px name = UC San Diego School of Medicine motto = Fiat lux (Let There Be Light) established =1969 type =Public endowment = staff = faculty = dean =David A. Brenner undergrad = postgrad = doctoral = city =La… …   Wikipedia

  • Alzheimer's disease clinical research — As of August 2010 there were more than 800 clinical trials under way to understand and treat Alzheimer s disease. 149 of these studies were human phase three trials, the last step before U.S. Food and Drug Administration approval and marketing.… …   Wikipedia

  • Etanercept — ] juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα. This therapeutic potential is based on the fact that TNF alpha is the master… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”